Dendreon Plans to Make PROVENGE Available in Europe

March 3, 2014 Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom. Dendreon will make PROVENGE commercially available to patients within the approved label through Centers of Excellence using its Contract Manufacturing Organization, PharmaCell. Centers of Excellence are institutions where a high volume of prostate cancer …

BiondVax Meets with the US Biomedical Advanced Research and Development Authority (BARDA) to Present the Use of its Universal Flu Vaccine

BiondVax Pharmaceuticals Ltd, developer of a universal flu vaccine, announced today that the Company has just returned from a meeting with officials at the Biomedical Advanced Research and Development Authority/Health and Human Services (BARDA/HHS) at which clinical trial results for BiondVax’s universal flu vaccine, the Multimeric 001, was presented. BiondVax was invited to give this seminar to the Influenza Division at BARDA, …

Self-Administration of Flu Vaccine with a Patch May be Feasible

February 26, 2014 The annual ritual of visiting a doctor’s office or health clinic to receive a flu shot may soon be outdated, thanks to the findings of a new study published in the journal Vaccine. The research, which involved nearly 100 people recruited in the metropolitan Atlanta area, found that test subjects could successfully apply a prototype vaccine patch to …

Researchers Discover New Target for Dengue Virus Vaccine

February 26, 2014 Creating a vaccine that protects people from all four types of dengue virus has frustrated scientists for decades. But researchers at the University of North Carolina have discovered a new target for human antibodies that could hold the key to a vaccine for the world’s most widespread mosquito-borne disease: dengue virus. Using an experimental technique new to …

Daiichi Sankyo and UMN Pharma Enter into Research Agreement for Norovirus Vaccine

February 14, 2014 Daiichi Sankyo and UMN Pharma Inc. today announced the conclusion of a collaborative research agreement for norovirus vaccine. Norovirus is one of the leading causes of infectious gastroenteritis and the number of infected people reported is increasing both in Japan and globally. While norovirus vaccine has not been approved in any countries, approximately 200,000 deaths of children …

Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio’s Proprietary Technology

February 10th, 2014 iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The vaccine candidate was produced on the company’s proprietary iBioLaunch™ platform by the Fraunhofer USA Center for Molecular Biotechnology. The text describing the program, released …

NanoViricides Partners with Viroclinics Biosciences

February 4th, 2014 NanoViricides, Inc. reported today that it has signed a “confidential disclosure agreement” (“CDA”) with Viroclinics Biosciences, BV (“Viroclinics”), a spinoff of the Department of Viroscience at the Erasmus Medical Centre (“Erasmus”) in Rotterdam, the Netherlands. The agreement will allow the scientists at Viroclinics to develop a specific proposal for the testing of different nanoviricides , such as …